Neurocrine Biosciences, Inc.(NBIX)
NASDAQ
$143.47
-2.04 (-1.40%)

Neurocrine Biosciences, Inc.(NBIX)Stock Forecast 2027 & Price Targets
NASDAQ

NBIX Stock Forecast Chart

NBIX Stock Forecast 2027: Price Prediction, Price Target & Outlook

Tickzen modelOct 2027 forecast, scaled to the latest close of $143.47

80% of modelled outcomes finish between

$99.69 – $248.56

−31% to +73% from today's $143.47 · 60% chance of finishing above today's price

NBIX Bear Case Forecast 2027

$99.69

−31% vs today

10% probability of finishing below $99.69

NBIX Median Forecast 2027

$157.42

+9.7% vs today

Midpoint of the range, not a price target

NBIX Bull Case Forecast 2027

$248.56

+73% vs today

10% probability of finishing above $248.56

Short-Term Signal: NeutralBased on price below its 50-day average and positive MACD momentum. View technical factors →
6M + 12M
  • Historical
  • Forecast median
  • 80% range
Tickzen model
NBIX model forecast
Statistical ranges built from price history alone. No analyst opinions in this part.

NBIX Price Probability

Tickzen's model has a median Oct 2027 outcome of $157.42 (+9.7%) for NBIX. Its 80% modelled range is $99.69 to $248.56.

Median outcome
$157.42
+9.7%
Above today
60%
chance of finishing higher
80% range
$100–$249
−31% to +73% vs today
  • Above today’s price60%
    above $143.47
  • Up 10% or more50%
    above $157.82
  • Up 25% or more36%
    above $179.34
  • Up 50% or more19%
    above $215.20
  • Down 10% or more29%
    below $129.12
  • Down 25% or more14%
    below $107.60
  • Down 50% or more1%
    below $71.74
  • Today $143.47
  • Model median $157.42
  • Analyst mean $207.81
  • 80% range

Hover the curve for the chance of finishing above any price.

These probabilities reflect the model's historical range distribution, not guaranteed returns.

Scenario Analysis Chart

Monthly NBIX Forecast

Tickzen model, prices in US dollars (USD): low, median and high at each month-end (the last row is the final forecast session, about one year out). The range holds 80% of modelled outcomes.

MonthLowMedianHigh
Nov 2026$121$146$175
Dec 2026$117$147$184
Jan 2027$114$148$192
Feb 2027$111$149$199
Mar 2027$109$150$207
Apr 2027$107$151$214
May 2027$105$153$221
Jun 2027$104$154$228
Jul 2027$102$155$235
Aug 2027$101$156$242
Sep 2027$99.75$157$248
Oct 2027$99.69$157$249

Model historical accuracy

In historical tests across 300 stocks and 10 start dates, prices finished inside the model's 80% range about 80% of the time across the tested horizons.

80%
3 months
80%
6 months
82%
12 months

See methodology →

Wall Street analysts
NBIX analyst forecast
What the Wall Street analysts covering the stock say. These are opinions, kept separate from the model.

Neurocrine Biosciences, Inc. Analyst Consensus & Target Price

Wall Street sentiment and price target analysis for NBIX

STRONG BUY

Consensus based on 29 analysts

Mean Target Price
$207.81+44.8%
Median Target$214.00
High Target$253.00
Low Target$164.00
Number of Opinions29

Price Target Analysis

Target Range: $164.00 - $253.00

Current vs Mean Target: +44.8%

Analyst Coverage: 29 firms tracking

What the analysts say

Current29 ratings
3 months ago28 ratings
  • Strong buy 4
  • Buy 21
  • Hold 4
  • Sell 0
  • Strong sell 0

86% of analysts rate it buy or strong buy, unchanged from 3 months ago.

NBIX analyst actions and price-target changes

Rating moves and price targets published by the firms covering NBIX.

Upgrades / downgrades
0 / 0
last 90 days
Targets raised / cut
18 / 2
last 90 days
Latest median target
$210
15 firms · +46.4% vs today

Price targets since Apr 10, 2026

  • Raised
  • Lowered
  • New target
  • Unchanged
  • Today $143.47

Latest actions

  • UBSTarget cutSep 29, 2026
    BuyTarget $214 (from $231, −7.4%)
  • Morgan StanleyTarget raisedSep 11, 2026
    Equal-WeightTarget $183 (from $182, +0.5%)
  • CitigroupTarget raisedSep 3, 2026
    BuyTarget $253 (from $249, +1.6%)
  • Morgan StanleyTarget cutAug 13, 2026
    Equal-WeightTarget $182 (from $196, −7.1%)
  • Canaccord GenuityTarget raisedAug 3, 2026
    BuyTarget $210 (from $200, +5.0%)

NBIX earnings and revenue estimates

What analysts expect the company to report next, and the catalyst that will test it.

Next earnings report

Earnings history →

Nov 3, 2026 in 25 days

EPS estimate
$1.96
Revenue estimate
$1.1B

Earnings per share

  • Current quarter$2.74$2.07$3.39+26%16
  • Next quarter$2.84$2.13$3.65+51%16
  • Current year$10.23$8.98$11.35+60%16
  • Next year$11.88$8.37$17.67+16%16

Revenue

  • Current quarter$1.0B$1.0B$1.1B+32%23
  • Next quarter$1.1B$1.0B$1.2B+35%22
  • Current year$3.9B$3.8B$4.1B+36%25
  • Next year$4.5B$4.3B$5.2B+17%24

NBIX: Tickzen Forecast vs Wall Street Targets

Tickzen's statistical range and the street's published targets on one price axis.

Tickzen median
$157.42
+9.7% vs today
Wall Street mean target
$207.81
+44.8% vs today
Difference
+32.0%
Wall Street above Tickzen
52-week rangewhere it has traded
Low $122.14High $186.12
Model range, Oct 2027Tickzen model, 80% of outcomes
Low $99.69Median $157.42High $248.56
Analyst targetsWall Street, 12-month
Low $164.00Median $214.00Mean $207.81High $253.00

Dashed line: today's price $143.47

The analyst mean target of $207.81 is 32.0% above the model's median of $157.42 for Oct 2027. It sits near the upper end of Tickzen's model range.

The model's Oct 2027 upper range of $248.56 is above NBIX's 52-week high of $186.12, and its lower range of $99.69 is below the 52-week low of $122.14.

They answer different questions: the model's range shows how far NBIX has typically moved, while analyst targets are opinions about what it is worth.

How Tickzen calculates the NBIX forecast range

The range is based on NBIX's own historical price volatility and the model's forecast distribution: 80% of modelled outcomes fall inside it, 10% above and 10% below. The model uses daily price history only; analyst targets are shown separately and are not an input.

Central 80% prediction interval at the end of each period from a lognormal model scaled by the stock's own realised volatility (sqrt-time growth); base is the median path (long-run drift plus a shrunk Prophet trend).

Volatility the model uses
36% a year
blend of the last 6 and 24 months
Volatility, last 30 days
22% a year
latest 20 trading days
Deepest drop
−25.4%
peak to trough, past 2 years
Beta vs S&P 500
0.64
swings less than the market
Market regime
Balanced
Tickzen regime read

The model is a range model, not a price predictor: its centre line is today's price plus normal long-run growth, so the range matters more than any single number. Probabilities describe the model's distribution, not guaranteed returns.

95% of the analyst target range falls inside the model's 80% range.

Model details

  • Model confidence score: 66.5% (High). This is an indicator-agreement score, a heuristic blend of technical indicators, volume, volatility, analyst consensus, data quality and market regime. It is not a probability and has not been back-tested; the validated figures are under Model historical accuracy.
  • Version: tickzen-prophet-v2
  • Anchored to the Oct 2, 2026 close of $143.18
  • Generated Oct 5, 2026
  • Prices are scaled to the latest close: the model is multiplicative around its starting price, so every figure is multiplied by $143.47 / $143.18 = 1.002. The model is refitted on a schedule; the starting price follows the market.
  • Sources: Yahoo Finance prices and analyst data; earnings calendar from Yahoo Finance and Finnhub.